肉芽肿性多血管炎停用糖皮质激素和免疫抑制剂后的持续缓解:法国血管炎研究组登记数据
该研究基于法国血管炎研究组登记数据,评估795例GPA患者停用糖皮质激素和免疫抑制剂后持续缓解(SROT)的发生率及相关因素。结果显示,诊断后10年7%的患者达到SROT,且SROT患者更多接受静脉环磷酰胺诱导治疗和利妥昔单抗维持治疗。
要点
- GPA患者诊断后10年SROT率为7%,3年时为20%。
- SROT患者更常接受静脉环磷酰胺诱导治疗,输注次数更多。
- SROT患者更常使用利妥昔单抗维持治疗,5年时差异显著。
核心结论
- 常规治疗后,7%的GPA患者在诊断后10年达到停用治疗的持续缓解。
- 达到或维持SROT的患者与复发或持续治疗的患者在基线血管炎特征上无差异。
- SROT患者更多接受强化诱导治疗和利妥昔单抗维持治疗。
研究设计与样本
- 基于法国血管炎研究组登记数据的回顾性研究,纳入795例符合ACR和/或修订的Chapel Hill共识会议命名标准的GPA患者。
- SROT定义为停用糖皮质激素和免疫抑制剂后,Birmingham血管炎活动性评分0分持续至少6个月。
主要发现
- 诊断后3年,92例GPA患者达到SROT,与342例对照(复发和/或仍接受糖皮质激素或免疫抑制剂)比较,基线无差异。
- 3年SROT患者更常接受静脉环磷酰胺诱导治疗(P=0.01),中位输注次数更高(P=0.05)。
- 5年SROT患者接受更多环磷酰胺输注(P=0.03),更多接受利妥昔单抗维持治疗(P<0.001)。
- 3年时SROT患者接受利妥昔单抗维持治疗的比例高于对照(P=0.09)。
- 74例有10年随访数据的患者中,15例(20%)在3年达到SROT,5例(7%)在10年维持SROT。
关键数值与推荐
- SROT定义为Birmingham血管炎活动性评分为0且持续≥6个月,停用糖皮质激素和免疫抑制剂。
- GPA诊断需符合ACR分类标准和/或修订的Chapel Hill共识会议命名标准。
临床怎么用
- 对于GPA患者,强化诱导治疗(如静脉环磷酰胺)和利妥昔单抗维持治疗可能与更高的持续缓解率相关。
- 停用治疗后持续缓解在GPA中不常见,10年时仅7%的患者维持SROT。
局限性
- 回顾性登记研究,可能存在选择偏倚和信息偏倚。
- 10年随访数据仅来自74例患者,样本量较小。
- 未报告多因素分析校正混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data on sustained remission of granulomatosis with polyangiitis (GPA) after discontinuation of therapy (referred to as GPA with sustained remission off-therapy [SROT]) are scarce. In the present study, SROT among GPA patients from the French Vasculitis Study Group Registry was evaluated to identify factors associated with its occurrence and durability. METHODS: For inclusion of patients in the study, the diagnosis of GPA had to meet the GPA classification criteria defined by the American College of Rheumatology and/or the revised Chapel Hill Consensus Conference nomenclature for vasculitis. SROT was defined as achievement of remission (a Birmingham Vasculitis Activity Score of 0) that was sustained for ≥6 consecutive months after having discontinued glucocorticoid (GC) and immunosuppressant treatments. The characteristics of the patients at baseline and treatments received were compared at 3, 5, and 10 years postdiagnosis according to whether or not SROT had been reached and maintained. RESULTS: Among 795 patients with GPA, 92 GPA patients with SROT at 3 years postdiagnosis were compared to 342 control subjects who had experienced disease relapse and/or were still receiving GCs or immunosuppressants. No baseline differences were found, but patients with SROT at 3 years postdiagnosis had more frequently received intravenous cyclophosphamide as induction therapy compared to control subjects (P = 0.01), with a higher median number of infusions (P = 0.05). At 5 years postdiagnosis, no baseline differences were observed between groups, but patients with SROT at 5 years postdiagnosis had received more cyclophosphamide infusions compared to control subjects (P = 0.03). More patients with SROT had received rituximab as maintenance therapy than control subjects at 3 years and 5 years postdiagnosis (P = 0.09 and P < 0.001, respectively). Of the 74 patients enrolled in the GPA Registry with 10-year follow-up data after having received conventional maintenance therapy, 15 (20%) had reached SROT at 3 years, and 5 (7%) maintained SROT at 10 years postdiagnosis. CONCLUSION: After conventional therapies, 7% of GPA patients had reached SROT at 10 years postdiagnosis. No baseline vasculitis characteristics distinguished patients who achieved/maintained SROT from those who experienced disease relapse and/or those who continued to receive GCs or immunosuppressant therapy, but patients with SROT had received more intensive induction therapy and rituximab as maintenance therapy more frequently.
引用
- Puéchal X, Iudici M, Pagnoux C, et al. Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. Arthritis Rheumatol. 2021. PMID: 33029946. doi:10.1002/art.41551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。